SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has sold one of its WavSTAT(R) Optical Biopsy Systems to the Almeda Company of Prague, Czech Republic. The device will be used at the University of Prague during colonoscopy to determine if tissue is normal, pre-cancerous or cancer.
Generally, doctors search for polyps, which are abnormal growths that stick out from the colon lining and can turn into cancer. However, another type of growth is much more dangerous and harder to see because it is flat or depressed and similar in color to healthy tissue. The WavSTAT uses an optical probe in conjunction with a colonoscope to determine within seconds if these flat or depressed lesions are cancerous or pre-cancer with greater than 96% accuracy.
Michel Vaudry, SpectraScience's Director of International Sales said, "The Czech Republic has one of the highest instances of colorectal cancer in the world. Our Czech partner, the Almeda Company, sees a large opportunity in helping physicians detect these flat 'polyps' at an early stage. In a recent study, it was found that close to 10% of patients had flat lesions, and that these lesions were five times as likely as polyps to contain cancerous or precancerous tissue. The flat or depressed lesions accounted for 15 percent of the potentially cancerous growths found in the study, but were involved in half of the cancers."
Vaudry continued, "The feeling amongst physicians that we have spoken with in the Czech Republic is that the WavSTAT is a wonderful adjunctive tool to aid in early detection of these flat lesions. We are now exploring additions to our export team in other European countries such as Italy, Germany and France."
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-KSB and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward- looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-KSB and other documents.
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that
designs, develops, manufactures and markets spectrophotometry systems
capable of determining whether tissue is normal, pre-cancerous or cancerous
without physically removing tissue from the body. The WavSTAT Optical
Biopsy System uses light to optically scan tissue and provides the
physician with an immediate analysis. With FDA approval for sale in the
U.S. and the CE Mark for the European Union, the WavSTAT System is the
first commercially available product that incorporates this innovative
technology for clinical use. The Company's LUMA(R) cervical imaging
technology has received FDA approval as an optical non-invasive system that
is proven to more effectively detect cervical cancer precursors than
conventional methods available in the market today.
Jim Hitchin, Chief Executive Officer
(858) 847-0200 x201
|SOURCE SpectraScience, Inc.|
Copyright©2008 PR Newswire.
All rights reserved